New Zealand markets closed

BIIB Jan 2025 270.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
10.100.00 (0.00%)
As of 11:45AM EST. Market open.
Full screen
Previous close10.10
Open12.10
Bid10.30
Ask11.30
Strike270.00
Expiry date2025-01-17
Day's range10.10 - 10.40
Contract rangeN/A
Volume2
Open interest66
  • Investor's Business Daily

    Is Eli Lilly Stock A Buy As Amgen Enters The Red-Hot Weight-Loss Ring?

    There's a growing field of competitors in the weight-loss drugs space, where Lilly and Novo currently dominate. Is Eli Lilly stock a buy?

  • GlobeNewswire

    Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

    SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS affecting less than 1,000 people in Europe1With QALSODY, Biogen has advanced the role of neurofilament in the development of new medicines for ALS, with the potential to accelerate further discovery in the field CAMBRIDGE, Mass., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opin

  • Reuters

    UPDATE 2-EU medicines regulator backs Biogen's ALS drug

    Europe's medicines regulator on Friday recommended granting a marketing authorization to Biogen's drug for the deadly and progressive neurodegenerative disease known as amyotrophic lateral sclerosis (ALS). The drug, Qalsody, received accelerated approved in the United States in April last year, based on preliminary data that showed it reduced levels of a neurofilament protein that scientists believe is tied with progression of the disease. ALS is a rare neurological disease that can affect nerve cells in the brain and spinal cord responsible for muscle movements, leading to progressive paralysis and death.